Covid-19 and Rehabilitation Outcomes: A Case-Control Study

被引:1
|
作者
Petzold, Stefanie [1 ]
Carney, Roisin [2 ]
Kool, JanPieter [3 ]
Bachmann, Stefan [4 ,5 ]
机构
[1] Kliniken Valens Rehazentrum Walenstadtberg, Klin Muskuloskelettale & Internist Rehabiltat, Walenstadt, Switzerland
[2] Kliniken Valens Rehazentrum Walenstadtberg, Physiotherapien, Walenstadt, Switzerland
[3] Forschungsabteilung, Kliniken Valens Rehazentrum Valens, Valens, Switzerland
[4] Kliniken Valens Rehazentrum Valens, Klin Muskuloskelettale & Internist Rehabil, Taminapl 1, CH-7317 Valens, Switzerland
[5] Univ Bern, Univ Hosp Bern, Dept Geriatr, Inselspital,Fac Med, Bern, Switzerland
关键词
Sars-CoV-2; Covid-19; rehabilitation; therapy; outcomes; COHORT;
D O I
10.1055/a-1729-7706
中图分类号
R49 [康复医学];
学科分类号
100215 ;
摘要
Objective Does the rehab process of acutely ill Covid-19 patients differ from recovered Covid-19 patients and other rehab patients? Comparison of the reha-course between acutely ill Covid-19 patients, recovered patients and rehab patients without Covid-19. Design: case-control study. Material and Methods Patients assigned to rehab in the period from 01.04 to 30.06.2020 with active Covid-19 disease (IG), recovered Covid-19 patients (PCG) and simultaneously rehabilitated persons matched by age, gender and comorbidity (Ko) were included. The primary endpoint was ADL- independence (FIM), secondary endpoints were quality of life (EQ5D-VAS), physical and mental health (PROMIS10) and mobility (TUG and 6MWT). Results 101 patients were included: IG=15; PCG=22; Ko=64. At entry, ADL-independence and quality of life were significantly highest in the IG (FIM IG 95.3 vs. PCG 78.3, vs. Ko 79.6; ANOVA p=0.029; EQ5D-VAS IG 56.1 vs. PCG 36.6 vs. Ko 51.0; ANOVA p=0.010). There were no differences in PROMIS10 and mobility. All three groups improved significantly from entry to discharge. The IG performed best in the FIM (IG 109.7 vs. PCG 97.2 vs. Ko 93.6; ANOVA p=0.039). The control group achieved the worst results with regard to mobility at discharge (TUG Ko 19.3 sec vs. 9.6 sec IG and 8.3 sec PCG). In the 6MWT, the PCG showed the best result (471 m vs. IG 416 m and Ko 389 m; difference n.s.). Conclusion All three patient groups benefited well from the rehab program. In addition, rehab measures bring a benefit also for isolated Covid-19 patients. In particular, recovered Covid-19 patients benefit greatly from the rehab program.
引用
收藏
页码:17 / 27
页数:11
相关论文
共 50 条
  • [21] Baseline procalcitonin as a predictor of bacterial infection and clinical outcomes in COVID-19: A case-control study
    Atallah, Natalie J.
    Warren, Hailey M.
    Roberts, Matthew B.
    Elshaboury, Ramy H.
    Bidell, Monique R.
    Gandhi, Ronak G.
    Adamsick, Meagan
    Ibrahim, Maryam K.
    Sood, Rupali
    Eddine, Savo Bou Zein
    Cobler-Lichter, Matthew J.
    Alexander, Natalie J.
    Timmer, Kyle D.
    Atallah, Christine J.
    Viens, Adam L.
    Panossian, Vahe S.
    Scherer, Allison K.
    Proctor, Teddie
    Smartt, Sherrie
    Letourneau, Alyssa R.
    Paras, Molly L.
    Johannes, Sascha
    Wiemer, Jan
    Mansour, Michael K.
    PLOS ONE, 2022, 17 (01):
  • [22] Evaluation of the COVID-19 vaccine effectiveness on the outcomes of COVID 19 disease in Iran: a test-negative case-control study
    Shadmani, Fatemeh Khosravi
    Moradi, Ghobad
    Naghipour, Mohammadreza
    Asadi, Fatemeh Torkaman
    Ahmadi, Ali
    Mirahmadizadeh, Alireza
    Haghdoost, Ali Akbar
    Mesgarpour, Bita
    Zahraei, Seyed Mohsen
    Goya, Mohammad Mehdi
    Mokhtari, Majid
    Safari-Faramani, Roya
    Zare, Fariba Zomorrodi
    Chegeni, Maryam
    Najafi, Farid
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [23] Chronic hydroxychloroquine therapy and COVID-19 outcomes: A retrospective case-control analysis
    Rangel, Lauren K.
    Shah, Payal
    Lo Sicco, Kristen
    Caplan, Avrom S.
    Femia, Alisa
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (06) : 1769 - 1772
  • [24] Intravenous Immunoglobulin for Treatment of Patients with COVID-19: A Case-control Study
    Khodashahi, Rozita
    Naderi, Hamid Reza
    Sedaghat, Alireza
    Allahyari, Abolghasem
    Sarjamee, Soroush
    Eshaghi, Soudabe
    Fazeli, Farzaneh
    Hoseini, Benyamin
    Dadgarmoghaddam, Maliheh
    Khodashahi, Mandana
    ARCHIVES OF CLINICAL INFECTIOUS DISEASES, 2021, 16 (01):
  • [25] Efficacy and Cardiovascular Safety of Remdesivir in COVID-19: A Case-Control Study
    Lakshmanan, Mageshwaran
    Chittaranjan, Vinothkumar
    Raju, Shanley-Abhishek
    Palanisamy, Priya Dharshini
    JOURNAL OF YOUNG PHARMACISTS, 2023, 15 (04) : 716 - 724
  • [26] Covid-19 infection in pregnant women in Dubai: a case-control study
    Hazari, Komal Sundeep
    Abdeldayem, Rasha
    Paulose, Litty
    Kurien, Nimmi
    Almahloul, Zukaa
    Mohammad, Hozaifah
    Elgergawi, Taghrid Faek A.
    Alkhanbouli, Maryam
    Mahmoud, Khalid
    Fazari, Atif Bashir
    Hassan, Amar
    Bayoumi, Riad
    BMC PREGNANCY AND CHILDBIRTH, 2021, 21 (01)
  • [27] Dermatologic comorbidities of the patients with severe COVID-19: A case-control study
    Kutlu, Omer
    ogut, Neslihan Demirel
    Erbagci, Ece
    Metin, Ahmet
    DERMATOLOGIC THERAPY, 2021, 34 (01)
  • [28] COVID-19 epidemiology in rheumatic diseases in Tuscany: A case-control study
    Francesconi, Paolo
    Cantini, Fabrizio
    Profili, Francesco
    Mannoni, Alessandro
    Bellini, Benedetta
    Benucci, Maurizio
    JOINT BONE SPINE, 2021, 88 (03)
  • [29] COVID-19 hospitalized patients and oral changes: a case-control study
    Ferreira, Marceli Dias
    Lopez, Lourdes Zeballos
    da Silva, Fernanda Pereira
    Mileo, Fernanda Couto
    Bortoluzzi, Marcelo Carlos
    dos Santos, Fabio Andre
    CLINICAL ORAL INVESTIGATIONS, 2023, 27 (08) : 4481 - 4491
  • [30] Chronic kidney disease and COVID-19 infection: A case-Control study
    Moeinzadeh, Firouzeh
    Mortazavi, Mojgan
    Shahidi, Shahrzad
    Mansourian, Marjan
    Yazdani, Akram
    Zamani, Zahra
    Seirafian, Shiva
    ADVANCED BIOMEDICAL RESEARCH, 2022, 11 (01):